Neurocognitive screening tools in HIV/AIDS: Comparative performance among patients exposed to antiretroviral therapy

HIV Medicine

Volumn 10, Issue 4, 2009, Pages 246-252

  Skinner, S ^a   Adewale, A J ^b   Deblock, L ^a   Gill, M J ^c   Power, Christopher ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Dementia; Highly active antiretroviral therapy; HIV 1; Neuropsychology; Screening tool

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COGNITIVE DEFECT; COMPARATIVE STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DRUG EXPOSURE; HIV DEMENTIA SCALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL HIV DEMENTIA SCALE; MINI MENTAL STATE EXAMINATION; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PSYCHOLOGIC TEST; REFERENCE VALUE; AIDS DEMENTIA COMPLEX; CD4 LYMPHOCYTE COUNT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MALE; MENTAL HEALTH; MIDDLE AGED; PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; STANDARDS;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SENSITIVITY AND SPECIFICITY;

EID: 62749188301     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00679.x     Document Type: Article

References (31)

1. World Health Organization. '3 by 5' Progress Report, December 2004. World Health Organization and Joint United Nations Programme on HIV/ AIDS, 2004.
2. Pandya R, Krentz HB, Gill MJ, Power C. HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci 2005; 32: 201-204.
3. Yeung H, Krentz HB, Gill MJ, Power C. Neuropsychiatric disorders in HIV infection: Impact of diagnosis on economic costs of care. AIDS 2006; 20: 2005-2009.
4. Antinori A, Arendt G, Becker JT et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-1799.
5. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8 (Suppl. 2): 115-121.
6. Brew BJ, Halman M, Catalan J et al. Factors in AIDS dementia complex trial design: Results and lessons from the abacavir trial. PLoS Clin Trials 2007; 2: E13.
7. Power C, McArthur JC, Johnson RT et al. Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol 1994; 68: 4643-4649.
8. Ellis RJ, Deutsch R, Heaton RK et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 1997; 54: 416-424.
9. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and related cognitive disorders. Neurology 1998; 50: 645-651.
10. Ellis R, Langford D, Masliah E. HIV and antiretroviral therapy in the brain: Neuronal injury and repair. Nat Rev Neurosci 2007; 8: 33-44.
11. Heaton RK, Marcotte TD, Mindt MR et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004; 10: 317-331.
12. Heaton RK, Velin RA, McCutchan JA et al. Neuropsychological impairment in human immunodeficiency virus infection: Implications for employment. HNRC Group. HIV Neurobehavioral Research Center. Psychosom Med 1994; 56: 8-17.
13. Hinkin CH, Hardy DJ, Mason KI et al. Medication adherence in HIV-infected adults: Effect of patient age, cognitive status, and substance abuse. AIDS 2004; 18 (Suppl. 1): S19-S25.
14. Barclay TR, Hinkin CH, Castellon SA et al. Age-associated predictors of medication adherence in HIV-positive adults: Health beliefs, self-efficacy, and neurocognitive status. Health Psychol 2007; 26: 40-49.
15. Power C, Selnes OA, Grim JA, McArthur JC. HIV Dementia Scale: A rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 273-278.
16. Sacktor NC, Wong M, Nakasujja N et al. The International HIV Dementia Scale: A new rapid screening test for HIV dementia. AIDS 2005; 19: 1367-1374.
17. Jones BN, Teng EL, Folstein MF, Harrison KS. A new bedside test of cognition for patients with HIV infection. Ann Intern Med 1993; 119: 1001-1004.
18. Berghuis JP, Uldall KK, Lalonde B. Validity of two scales in identifying HIV-associated dementia. J Acquir Immune Defic Syndr 1999; 21: 134-140.
19. Grassi MP, Perin C, Borella M, Mangoni A. Assessment of cognitive function in asymptomatic HIV-positive subjects. Eur Neurol 1999; 42: 225-229.
20. Selnes OA, Jacobson L, Machado AM et al. Normative data for a brief neuropsychological screening battery. Multicenter AIDS Cohort Study. Percept Mot Skills 1991; 73: 539-550.
21. Paton NI. Treatment interruption strategies: How great are the risks? Curr Opin Infect Dis 2008; 21: 25-30.
22. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Neurology 1996; 47: 1247-1253.
23. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
24. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988; 44: 837-845.
25. Zhou XH, Obuchowski NA, McClish DK. Statistical Methods in Diagnostic Medicine. New York: Wiley, 2002.
26. Power C, Johnson RT. HIV-1-associated dementia: Clinical features and pathogenesis. Can J Neurol Sci 1995; 22: 92-100.
27. Ganasen KA, Fincham D, Smit J, Seedat S, Stein D. Utility of the HIV Dementia Scale (HDS) in identifying HIV dementia in a South African sample. J Neurol Sci 2008; 269: 62-64.
28. Wojna V, Skolasky RL, McArthur JC et al. Spanish validation of the HIV Dementia Scale in women. AIDS Patient Care STDS 2007; 21: 930-941.
29. Morgan EE, Woods SP, Scott JC et al. Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol 2008; 30: 83-90.
30. Riedel D, Ghate M, Nene M et al. Screening for human immunodeficiency virus (HIV) dementia in an HIV clade C-infected population in India. J Neurovirol 2006; 12: 34-38.
31. von Giesen HJ, Haslinger BA, Rohe S, Koller H, Arendt G. HIV Dementia Scale and psychomotor slowing - the best methods in screening for neuro-AIDS. J Neuropsychiatry Clin Neurosci 2005; 17: 185-191.